People · Operator
Named in public records as an officer, director or promoter · active 2026–2026 · Biotech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TetraScience, Inc. | — | Biotech | Series C | $66.0M | $72.1M | 2026 |
Christopher S. Lynch at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher S. Lynch on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Deven Parekh | 1 | 21 |
| Michael Skok | 1 | 12 |
| Chris Lynch | 1 | 6 |
| Patrick Grady | 1 | 5 |
| Remy S. Evard | 1 | 1 |
| Maurice Bedoni | 1 | 1 |
| Remy Evard | 1 | 1 |
| Salvatore Savo | 1 | 1 |
| Deven S. Parekh | 1 | 1 |
| Siping Wang | 1 | 1 |
| James S. Orsillo | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.